The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
20,284
Time to the First Occurrence of Composite Endpoint of Stroke and Non-central nervous system (CNS) Systemic Embolism
Time to the first occurrence of composite endpoint of stroke and non-CNS systemic embolism will be reported.
Time frame: Up to 4 years
Time to the First Occurrence of International Society of Thrombosis and Hemostasis (ISTH) Major Bleeding
Time to the first occurrence of ISTH major bleeding will be reported.
Time frame: Up to 4 years
Time to the First Occurrence of the Composite of ISTH Major and Clinically Relevant Non-major (CRNM) Bleeding
Time to the first occurrence of the composite of ISTH major and CRNM bleeding will be reported.
Time frame: Up to 4 years
Time to the First Occurrence of Composite Endpoint of Stroke, Non-CNS Systemic Embolism and ISTH Major Bleeding
Time to the first occurrence of composite endpoint of stroke, non-CNS systemic embolism and ISTH major bleeding will be reported.
Time frame: Up to 4 years
Time to the First Occurrence of Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, and Non-CNS Systemic Embolism
Time to the first occurrence of composite endpoint of CV death, MI, stroke, and non-CNS systemic embolism will be reported.
Time frame: Up to 4 years
Time to CV Death
Time to CV death will be reported.
Time frame: Up to 4 years
Time to the First Occurrence of Composite Endpoint of All-cause Death, MI, Stroke and Non-CNS Systemic Embolism
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Apixaban matching apixaban placebo will be administered orally.
Advanced Cardiovascular, LLC
Alexander City, Alabama, United States
Ascension St. Vincent's Health System
Birmingham, Alabama, United States
SEC Clinical Research
Dothan, Alabama, United States
HH Heart Center and Heart Center
Huntsville, Alabama, United States
CB Flock Research Corporation
Mobile, Alabama, United States
Mercy Gilbert Medical Center
Gilbert, Arizona, United States
Valleywise Health Medical Center
Phoenix, Arizona, United States
Arizona Arrhythmia Research Center
Phoenix, Arizona, United States
Arizona Heart Hospital
Phoenix, Arizona, United States
HonorHealth Neurology
Scottsdale, Arizona, United States
...and 1031 more locations
Time to the first occurrence of composite endpoint of all-cause death, MI, stroke and Non-CNS systemic embolism will be reported.
Time frame: Up to 4 years
Time to the First Occurrence of Composite Endpoint of CV Death, MI, Stroke, Acute Limb Ischemia (ALI), and Urgent Hospitalization for Vascular cause of Ischemic Nature
Time to the first occurrence of composite endpoint of CV death, MI, stroke, ALI \[any unanticipated revascularization or amputation of ischemic limb\]), and urgent hospitalization for vascular cause of ischemic nature (including deep vein thrombosis \[DVT\] and pulmonary embolism \[PE\]) will be reported.
Time frame: Up to 4 years